BGI Manufacturing is focused on the development, production and sales of in vitro diagnostic reagents, medical devices, research reagents and equipments. On 30 June 2014, China Food and Drug Administration (CFDA) approved the registrations of BGI Manufacturing’s sequencers BGISEQ-1000 and BGISEQ-100. BGI became the first organization with the registration of next generation sequencing diagnostic products and medical devices.
These products can be applied for non-invasive prenatal testing and assisted diagnosis on fetal chromosomal aneuploidy diseases including Trisomy 21 (Down Syndrome), Trisomy 13 (Patau Syndrome), and Trisomy 18 (Edwards Syndrome), by sequencing cell-free fetal DNA in the maternal blood of high-risk pregnant women after 12 weeks of pregnancy.
For more information, please visit “CFDA Approved Next Generation Sequencing Diagnostic Products”.
BGI Manufacturing not only devotes itself to the product manufacture but also places emphasis on the research of life science, biotechnology and biomedical engineering to achieve an integrative model of research, technology and application development.